-+ 0.00%
-+ 0.00%
-+ 0.00%
Merck's Sac-TMT improves overall survival in Phase 3 advanced gastroesophageal cancer trial
Share
Listen to the news
Merck's Sac-TMT improves overall survival in Phase 3 advanced gastroesophageal cancer trial
  • Merck's sacituzumab tirumotecan improved overall survival versus physician-selected treatment in the Phase 3 TroFuse-015 trial, meeting its primary endpoint.
  • The trial enrolled patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two prior systemic therapies.
  • The drug did not meet the secondary endpoint of progression-free survival; no new safety signals emerged.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261120719582) on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending